MIT biologists found that a high-fat diet drives colon cancer cells to switch on YAP1, a regenerative program required for the cancer to spread to the liver. Drugs blocking ceramide production could help prevent metastasis.
If you’ve ever had an MRI, you’ve been inside the strongest magnet most people will ever get near. Those machines run at about 1.5 to 3 tesla, and hospitals respect them enough to screen every paperclip that enters the room. So when a fusion company outside Oxford, England, says its magnet system peaked at 13.7 tesla and held together, that number’s earned a second of your attention.
The company is Tokamak Energy, and the system is called Demo4: 44 superconducting coils arranged the way they’d wrap around a spherical tokamak, the squashed version of the classic donut-shaped fusion reactor, plus the cooling, power and control gear needed to run them as one machine. Tokamak Energy announced on September 9 that it had finished a 14-month test campaign on the whole assembly. And honestly, the 13.7 tesla wasn’t the number that got me. Demo4 spent roughly 10,000 hours energized over those 14 months, by the company’s count, including long stretches at high field.
Broadcom reported Q3 FY2026 revenue of $29.59 billion on September 2, with **Broadcom AI semiconductor revenue** hitting $16.7 billion — up 221% year over year and now 56.4% of total revenue. Q4 guidance puts AI at $21.7 billion, or 62.4% of the business. The company projects AI revenue doubling to $115 billion in fiscal 2027 and potentially $230 billion by 2028. For procurement teams, the signal is structural: the company that makes the custom chips powering AI infrastructure is now an AI company first, and its capacity allocation decisions will shape what industrial buyers can actually get.
Broadcom AI semiconductor revenue stopped being a growth story and became the core business this quarter. The company reported Q3 FY2026 results on September 2, showing total revenue of $29.59 billion, up 86% year over year. Within that, AI semiconductor revenue reached $16.7 billion, a 221% year-over-year increase and a 54% sequential jump.
That figure now represents 56.4% of total revenue and 80.1% of Broadcom’s semiconductor solutions segment. The company guided Q4 AI semiconductor revenue to $21.7 billion, which would be 62.4% of total revenue — a new record and a further 5.9 percentage point increase from Q3.
Cybersecurity Awareness Month 2026 marks a strategic turning point, as traditional awareness is no longer sufficient against rapidly evolving threats. AI now accelerates attacks at machine speed, exploiting vulnerabilities and enhancing ransomware’s sophistication. The expanding attack surface from IoT and cloud, coupled with vulnerable supply chains and the looming threat of quantum computing, demands a shift from static defense to proactive resilience. Ultimately, cybersecurity must become a continuous, adaptive process to counter the speed and convergence of modern threats.
Cell division inevitably shortens telomeric DNA owing to the end-replication problem. Eukaryotic chromosomes possess specialized telomere structures to maintain genomic stability. In most proliferative cells, telomerase adds telomeric repeats during S-phase. In differentiated cells where telomerase is silenced, telomeres shorten progressively, thereby compromising genomic integrity. Consequently, cancer cells universally activate alternative telomere maintenance mechanisms during malignant transformation: ~80% reactivate telomerase, while a portion of the rest rely on BIR (break-induced replication)–mediated homologous recombination-based ALT (alternative lengthening of telomeres). Although these mechanisms are stable once established, the initial determinants influencing a cancer cell’s choice remain poorly understood. This review discusses recent molecular insights into how telomeric chromatin properties profoundly impact this choice. After briefly introducing telomere chromatin characteristics and key players in its maintenance and dynamics, we discuss the mechanisms by which cancer cells acquire distinct telomere replication capabilities. In particular, we present an in-depth analysis linking telomere heterochromatin status to ALT. Furthermore, based on recent advances, we propose a coupled feedforward loop model explaining how the ALT state becomes “locked in” once initiated. Finally, we offer novel perspectives on rational, telomere-centric therapeutic interventions for ALT-positive cancers, focusing on strategies designed to disrupt such feedforward loops by manipulating telomeric chromatin structure.
🎧 Sony Walkman: https://link.amazon/B0i0MG1hE (Affiliate Link)(As an Amazon Associate, I earn from qualifying purchases)Are you entirely tired of constant s…